Acute myeloid leukemia therapeutics: CARs in the driver’s seat

Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardiros, Armen, Brown, Christine E, Budde, L Elizabeth, Wang, Xiuli, Forman, Stephen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916356/
https://www.ncbi.nlm.nih.gov/pubmed/24511454
http://dx.doi.org/10.4161/onci.27214
Descripción
Sumario:Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and future directions for this immunotherapy.

Ejemplares similares